An 8-week supplementation with n-3 PUFA (1200 mg ALA, 700 mg EPA, and 340 mg DHA) in patients with moderate-to-severe COPD reversed muscle wasting and improved the functional capacity compared with placebo, without any effect on FEV1 or systemic inflammatory markers (CRP, IL-6, and TNF-α) [119]. The gene discussed is IL6; the disease is chronic obstructive pulmonary disease.